Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2255-2266
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2255
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2255
CHEMO trials | Component | Median survival | P value |
GERCORD/GISCAD[66] | Gem ± oxaliplatin | 9.0 mo vs 7.1 mo | 0.13 |
Van Cutsem et al[67] | Gem ± tipifarnib | 193 d vs 182 d | 0.75 |
IRINOGEM[68] | Gem ± irinotecan | 6.3 mo vs 6.6 mo | 0.79 |
Von Hoff et al[69] | Gem ±nab-paclitaxel | 8.5 mo vs 6.7 mo | < 0.001 |
PRODIGE[70] | Gem vs FOLFIRINOX | 6.8 mo vs 11.1 mo | < 0.001 |
- Citation: He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: Where do we stand? World J Gastroenterol 2014; 20(9): 2255-2266
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2255.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2255